3f8 and leukine for neuroblastoma – pro

The proposed therapy is a clinical phase II trial performed at MSKCC. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining colony-stimulating factors, such as sargramostim, with monoclonal antibodies may be an effective treatment for advanced neuroblastoma. It is a Phase II trial to study the effectiveness of monoclonal antibody 3F8 plus sargramostim in treating patients who have advanced neuroblastoma.

Dr. Kushner’s team ahs completed a study of this regimen with a monoclonal antobody and has a manuscript that is ready for submission. There are no publications yet available to assess this therapy.

Click here to review prior Dilemmas of the Week

Participate in our Forums

To ask questions or participate in a discussion, please visit our Forums. You must LOGIN to participate.

Help Us Help Others

You can become a Site Sponsor. Or you may wish to support our work with a Donation.

Focused Articles For You

Lay Portal

Professional